University of Texas: Experimental Vaccine Against Respiratory Syncytial Virus Elicits Strong Immune Response
August 01, 2019
August 01, 2019
AUSTIN, Texas, Aug. 1 [TNSmedicalresearch] -- The University of Texas issued the following news release:
An experimental vaccine against respiratory syncytial virus (RSV), one of the leading causes of infectious disease deaths in infants, has shown early promise in a Phase 1 human clinical trial. A team of researchers, including The University of Texas at Austin's Jason McLellan, report today in the journal Science that one dose of their vaccine candidate elicited large increases in . . .
An experimental vaccine against respiratory syncytial virus (RSV), one of the leading causes of infectious disease deaths in infants, has shown early promise in a Phase 1 human clinical trial. A team of researchers, including The University of Texas at Austin's Jason McLellan, report today in the journal Science that one dose of their vaccine candidate elicited large increases in . . .